Cipla Q1 Results: Cons PAT rises 10% YoY to Rs 1,298 crore, revenue up 4%

Drug major Cipla on Friday reported a 10% year-on-year (YoY) growth in consolidated net profit to Rs 1,298 crore for the June quarter, compared to Rs 1,178 crore in the same period last year. The profit after tax (PAT) is attributable to the company’s shareholders.

Revenue from operations rose 4% to Rs 6,957 crore, up from Rs 6,693 crore in the corresponding quarter of the previous financial year.

The profit after tax (PAT) rose 6% sequentially from Rs 1,222 crore in Q4FY25, while revenue increased 3.4% from Rs 6,730 crore reported in the January–March quarter of FY25.

Cipla’s Earnings Before Interest, Taxes, Depreciation and Amortisation (EBITDA) stood at Rs 1,778 crore in the reported quarter, up 4% year-on-year. Meanwhile, the EBITDA margin saw a slight dip of 7 basis points to 25.6%.

The company’s profit before tax (PBT) stood at Rs 1,770 crore in the quarter under review, compared to Rs 1,611 crore in the year-ago period.

Cipla’s total debt was reported at Rs 459 crore as of June 30, 2025, while cash balance stood at Rs 10,838 crore and net cash at Rs 10,379 crore.The company crossed the threshold of Rs 3,000 crore for the first time in the opening quarter of any financial year. The company’s expenses grew 4% to Rs 5,179 crore in Q1FY26 versus Rs 4,978 crore in the year ago period.